转移性非小细胞肺癌免疫治疗与放疗的总生存:美国国家癌症数据库分析
基于美国国家癌症数据库2013至2014年44,498例IV期非小细胞肺癌患者,分析化疗或免疫治疗联合放疗与总生存的关系。多因素分析显示免疫治疗(HR 0.81)和立体定向放疗(SRT,HR 0.78)独立与总生存改善相关;接受SRT者中免疫治疗组中位总生存18.2个月 vs 化疗组14.3个月(p=0.004)。
要点
- 免疫治疗(HR 0.81,95%CI 0.78-0.83)和SRT(HR 0.78,95%CI 0.70-0.78)独立与总生存改善相关。
- 免疫治疗患者中,无放疗、EBRT和SRT的中位总生存分别为14.5、10.9和18.2个月(p<0.0001)。
- SRT患者中BED>60 Gy独立与总生存改善相关(HR 0.79,95%CI 0.70-0.90,p<0.0001)。
核心结论
- SRT与转移性非小细胞肺癌患者总生存改善相关,且不依赖于全身治疗方式;SRT联合免疫治疗的高生存率强烈支持开展随机试验评估。
研究设计与样本
- 回顾性分析美国国家癌症数据库2013至2014年接受化疗或免疫治疗的IV期非小细胞肺癌患者,共44,498例;放疗方式分为颅内和/或颅外SRT或非SRT外照射放疗(EBRT)。
主要发现
- 全队列中免疫治疗占13%,EBRT占46.8%,SRT占4.7%。
- 多因素分析显示免疫治疗(HR 0.81,95%CI 0.78-0.83)和SRT(HR 0.78,95%CI 0.70-0.78)独立与总生存改善相关,但SRT与免疫治疗的交互项无统计学意义(p=0.89)。
- 免疫治疗患者中,无放疗、EBRT和SRT的中位总生存分别为14.5、10.9和18.2个月(p<0.0001);多因素分析中EBRT(HR 1.37,95%CI 1.29-1.46)和SRT(HR 0.78,95%CI 0.66-0.93)与总生存相关。
- SRT亚组中,免疫治疗和化疗的中位总生存分别为18.2和14.3个月(p=0.004),多因素分析中免疫治疗与总生存相关(HR 0.82,95%CI 0.69-0.98)。
- 接受SRT的患者中,生物有效剂量(BED)>60 Gy独立与总生存改善相关(HR 0.79,95%CI 0.70-0.90,p<0.0001),且BED与全身治疗存在显著交互作用(p=0.008)。
局限性
- 原文为数据库回顾性分析,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). METHODS: The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: In total, 44,498 patients were included (13% immunotherapy, 46.8% EBRT, and 4.7% SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95% confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95%CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT + immunotherapy was insignificant (p = 0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2 months, respectively (p < 0.0001), and EBRT (HR:1.37, 95%CI:1.29-1.46) and SRT (HR:0.78, 95%CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3 months, respectively (p = 0.004), with immunotherapy (HR:0.82, 95%CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED) > 60 Gy was independently associated with improved OS (HR:0.79, 95%CI:0.70-0.90, p < 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p = 0.008). CONCLUSIONS: Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT + immunotherapy strongly argues for evaluation in randomized trials.
引用
- Foster CC, Sher DJ, Rusthoven CG, et al. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019. PMID: 30691492. doi:10.1186/s13014-019-1222-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。